Table 1.
Patient demographics in SSc cohort.
| Characteristic | ||
|---|---|---|
| Age (years) | 56.45 ± 13.60 | |
| Sex | Female | 29 (93.55) |
| SSc duration (years) | 7 (1–28) | |
| SSc subset | lcSScdcSSc | 3 (9.67)28 (90.33) |
| OHIP 49 | 43.68 (21.07) | |
| SHAQ | 0.92 (0.73) | |
| Autoantibody pattern | ANA positivity (negative for ACA and anti-Scl70) | 2 (6.45) |
| ACA | 10 (32.26) | |
| Anti-Scl 70 | 18 (58.06) | |
| Educational level | Primary school | 20 (64.52) |
| High school or more | 11 (35.48) | |
| mRSS | Mild/moderate | 22 (70.97) |
| Severe/end-stage | 9 (29.03) | |
| GI tract involvement | Present | 21 (67.74) |
| Joint/tendon involvement | Present | 27 (87.10) |
| Muscular involvement | Present | 21 (67.74) |
| Digital ulcers | Present | 6 (19.35) |
| Peripheral vascular involvement | Present | 27 (87.10) |
| Lung involvement | Present | 27 (87.10) |
| Chest radiography | Normal | 22 (70.97) |
| Intestinal lung disease | 9 (29.03) | |
| FVC | 91.23 ± 21.77 | |
| DLCO | 68.33 ± 20.16 | |
| Estimated sPAP | High | 4 (12.90) |
| Heart involvement | Present | 24 (77.42) |
Data are expressed as mean ± standard deviation, absolute number (%), or median (range).
SSc, systemic sclerosis; lcSSc, limited cutaneous systemic sclerosis; dcSSc, diffuse cutaneous systemic sclerosis; OHIP 49, Oral Health Impact Profile 49; SHAQ, Scleroderma Health Assessment Questionnaire; ANA, antinuclear antibodies; ACA, anti-centromere antibodies; Anti-Scl70, anti-Scl70 antibodies; mRSS, modified Rodnan skin score; GI, gastrointestinal; FVC, forced vital capacity, % predicted; DLCO, diffusing capacity for carbon monoxide, % predicted; sPAP, pulmonary artery systolic pressure.